PURPOSE: We analyzed the impact of allogeneic stem-cell transplantation (alloSCT) as an early consolidation for young patients with acute myeloblastic leukemia in first complete remission (CR1) through four successive protocols. PATIENTS AND METHODS: Of the 472 patients who achieved CR1, 182 (38%) had an HLA-identical sibling (donor group), and alloSCT was performed in 171 patients (94%). Of the 290 patients without donor (no-donor group), 62% received anautologous SCT. RESULTS: In an intent-to-treat analysis based on donor availability, the overall 10-year survival probability was 51% v 43% (P = .11) for the donor and no-donor groups, respectively. A Cox analysis determined that four factors had independent prognostic significance for survival (initial WBC count, French-American-British subtypes, cytogenetic risk, and number of induction courses). This permitted constitution of a simple index that reclassified 21% of the patients compared with usual cytogenetic classification and identified three subpopulations with different outcome and different impact of alloSCT. CONCLUSION:AlloSCT was associated with a survival advantage for an intermediate-risk group. In other groups, numbers are limited for definitive conclusion. However, early performed alloSCT does not seem to be the optimal treatment of high-risk patients or offer any advantage over intensive chemotherapy in low-risk patients.
RCT Entities:
PURPOSE: We analyzed the impact of allogeneic stem-cell transplantation (alloSCT) as an early consolidation for young patients with acute myeloblastic leukemia in first complete remission (CR1) through four successive protocols. PATIENTS AND METHODS: Of the 472 patients who achieved CR1, 182 (38%) had an HLA-identical sibling (donor group), and alloSCT was performed in 171 patients (94%). Of the 290 patients without donor (no-donor group), 62% received an autologous SCT. RESULTS: In an intent-to-treat analysis based on donor availability, the overall 10-year survival probability was 51% v 43% (P = .11) for the donor and no-donor groups, respectively. A Cox analysis determined that four factors had independent prognostic significance for survival (initial WBC count, French-American-British subtypes, cytogenetic risk, and number of induction courses). This permitted constitution of a simple index that reclassified 21% of the patients compared with usual cytogenetic classification and identified three subpopulations with different outcome and different impact of alloSCT. CONCLUSION: AlloSCT was associated with a survival advantage for an intermediate-risk group. In other groups, numbers are limited for definitive conclusion. However, early performed alloSCT does not seem to be the optimal treatment of high-risk patients or offer any advantage over intensive chemotherapy in low-risk patients.
Authors: Stephanie J Lee; Barry Storer; Hailin Wang; Hillard M Lazarus; Edmund K Waller; Luis M Isola; Thomas R Klumpp; John Bosco C Umejiego; Bipin N Savani; Alison W Loren; Mitchell S Cairo; Bruce M Camitta; Corey S Cutler; Biju George; H Jean Khoury; David I Marks; David A Rizzieri; Edward A Copelan; Vikas Gupta; Jane L Liesveld; Mark R Litzow; Alan M Miller; Harry C Schouten; Robert Peter Gale; Jean-Yves Cahn; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2013-09-06 Impact factor: 5.742
Authors: Philipp G Hemmati; Theis H Terwey; Gero Massenkeil; Philipp le Coutre; Lam G Vuong; Stefan Neuburger; Bernd Dörken; Renate Arnold Journal: Int J Hematol Date: 2010-02-25 Impact factor: 2.490
Authors: J J Cornelissen; J Versluis; J R Passweg; W L J van Putten; M G Manz; J Maertens; H B Beverloo; P J M Valk; M van Marwijk Kooy; P W Wijermans; M R Schaafsma; B J Biemond; M-C Vekemans; D A Breems; L F Verdonck; M F Fey; M Jongen-Lavrencic; J J W M Janssen; G Huls; J Kuball; T Pabst; C Graux; H C Schouten; A Gratwohl; E Vellenga; G Ossenkoppele; B Löwenberg Journal: Leukemia Date: 2014-11-27 Impact factor: 11.528
Authors: Joseph M Brandwein; Michelle Geddes; Jeannine Kassis; Andrea K Kew; Brian Leber; Thomas Nevill; Mitchell Sabloff; Irwindeep Sandhu; Andre C Schuh; John M Storring; John Ashkenas Journal: Am J Blood Res Date: 2013-05-05
Authors: John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler Journal: JAMA Date: 2009-06-10 Impact factor: 56.272
Authors: Ulas D Bayraktar; Marcos de Lima; Rima M Saliba; Molly Maloy; Hugo R Castro-Malaspina; Julianne Chen; Gabriela Rondon; Alexander Chiattone; Ann A Jakubowski; Farid Boulad; Nancy A Kernan; Richard J O'Reilly; Richard E Champlin; Sergio Giralt; Borje S Andersson; Esperanza B Papadopoulos Journal: Biol Blood Marrow Transplant Date: 2013-03-01 Impact factor: 5.742